*Analysts that SCRIPTS Asia was able to identify from the audio who spoke during Q&A.
Support
Japan
050.5212.7790
North America
1.800.674.8375
Tollfree
0120.966.744
Email Support
support@scriptsasia.com
1
Presentation
Moderator: I would like to move on to the medium-term strategy briefing.
Mr. Keisuke Suzuki, President and CEO, will explain the medium-term strategy.
Keisuke Suzuki: My name is Suzuki. Thank you for joining us.
Since I sent out the medium-term plan yesterday, I would like to discuss just a few key points with you.
We have changed our business portfolio considerably. We have downsized the coronary intervention business, resigned the Orsiro distributor contract, and as I mentioned earlier, we have transferred our shares in the Shenzhen factory that manufactures wires and valves related to this business and closed.
Then, as just mentioned, the RF Needle contract is also over. The blood purification business was transferred to another company. In this context, we have decided to focus on new areas, such as cerebrovascular or gastrointestinal.
Support
Japan
050.5212.7790
North America
1.800.674.8375
Tollfree
0120.966.744
Email Support
support@scriptsasia.com
2
This is the track record since the establishment. The right-hand side of the chart shows that the Company's share of JPY51.7 billion in sales in the previous fiscal year reached 54.9%.
These are our business segments.
3/4 are related to arrhythmia. We are now moving on the premise that we are in effect withdrawing from the coronary intervention area, rather than reducing it, in order to focus on the remaining areas: cardiovascular, cerebrovascular, and gastrointestinal areas.
Support
Japan
050.5212.7790
North America
1.800.674.8375
Tollfree
0120.966.744
Email Support
support@scriptsasia.com
3
This is about the market surrounding us.
In the market of JPY250 billion in our portfolio, we are currently making JPY51.7 billion.
This is about our business model, and of course we will continue to do business as a hybrid manufacturer and trading company.
Support
Japan
050.5212.7790
North America
1.800.674.8375
Tollfree
0120.966.744
Email Support
support@scriptsasia.com
4
Attachments
Original Link
Original Document
Permalink
Disclaimer
JLL - Japan Lifeline Co. Ltd. published this content on 15 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 May 2023 03:26:04 UTC.
Japan Lifeline Co., Ltd. is a Japan-based company mainly engaged in the import, manufacture and sale of cardiac circulators and other medical devices. The Company is mainly engaged in the production of rhythm devices, electrophysiological (EP) and ablations, surgical products and intervention products. The rhythm devices include cardiac pacemakers, implantable cardioverter defibrillator (ICD), cardiac resynchronization therapy defibrillator (CRT-D) and other rhythm devices. The EP and ablations include EP catheters for cardiac arrhythmia examination, ablation catheters for arrhythmia treatment and other EP and ablations. The surgical products include prosthetic heart valves and annuloplasty rings for heart disease surgical treatment, vascular grafts, open stent grafts and stent grafts for aortic disease treatment, as well as other surgical products. The intervention products include balloon catheters, guide wires, penetration catheters and other intervention products.
JAPAN LIFELINE CO., LTD. 
